Amorphex Therapeutics
Amorphex Therapeutics, a Massachusetts-based medical firm, innovates in ocular drug delivery technology.
Amorphex Therapeutics, a Massachusetts-based medical firm, innovates in ocular drug delivery technology.
Amorphex Therapeutics, founded in Andover, Massachusetts, is a medical firm focused on revolutionizing ocular drug delivery. Their core mission is to enhance the treatment of ophthalmic diseases through innovative technology. The company's flagship product, TODDD™ (Topical Ophthalmic Drug Delivery Device), is a patented, soft device designed to deliver drugs to the eye continuously for several months without interruption. This technology aims to improve patient compliance and treatment efficacy, particularly for conditions like glaucoma.
Notable figures associated with Amorphex Therapeutics include experts in ophthalmology and drug delivery systems, though specific names are not publicly highlighted. The company has garnered attention for its groundbreaking TODDD™ device, which represents a significant advancement in the field of ocular therapeutics. By offering a reliable and sustained drug delivery method, Amorphex Therapeutics has the potential to significantly impact the treatment landscape for chronic eye diseases, reducing the burden of daily medication administration and improving patient outcomes globally.
Companies similar to Amorphex Therapeutics include OcuMedic, EyePoint, On Demand Therapeutics and Mati Therapeutics.
Amorphex Therapeutics' headquarters is located in Andover, MA, US.
Amorphex Therapeutics' most recent funding round was for $265k (USD) in January 2023.
As of Jan 20, 2023, Amorphex Therapeutics has disclosed funding of $265k (USD). Undisclosed round amounts are excluded.
Amorphex Therapeutics has 6 employees as of Feb 4, 2024.
